The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas

Hellenic Journal of Nuclear Medicine

Volumn 13, Issue 1, 2010, Pages 40-44

  Kasper, Bernd ^a   Hohenberger, Peter ^a   Strauss, Ludwig G ^b   Dimitrakopoulou Strauss, Antonia ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

FDG; Prediction; Sarcomas; Treatment monitoring

Indexed keywords

DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IMATINIB;

BIOPSY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RECURRENCE RISK; REVIEW; SOFT TISSUE SARCOMA; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR RECURRENCE;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA;

EID: 77951861752     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Pisters P. Staging and Prognosis, in Pollock RE, Ed. American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamilton, Ontario: BC Decker, Inc.; 2002:80-88.
2. Standard-Options-Recommendations Vol1. Sarcome des Tissus Mous et Ostéosarcomes. Paris, France, Arnette Blackwell, 1995, pp 1-113.
3. Verweij J, Mouridsen HT, Nielsen OS et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201.
4. Pisters PW, Patel SR, Varma DG et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:3481-3487.
5. Meric F, Hess KR, Varma DG. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95:1120-1126. (Pubitemid 34925365)
6. Wendtner CM, Abdel-Rahman S, Krych M et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002;20:3156-3164. (Pubitemid 34791106)
7. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
8. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-373. (Pubitemid 44297249)
9. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev 2002;2:683-693. (Pubitemid 37328919)
10. Weber WA. Positron emission tomography as an imaging biomarker J Clin Oncol 2006;24:3282-3292. (Pubitemid 46622068)
11. 18F- fluorodeoxy-glucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215-1220.
12. Schulte M, Brecht-Krauss D, Heymer B et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a noninvasive determination of biological activity possible? Eur J Nucl Med 1999;26:599-605. (Pubitemid 29263630)
13. Bastiaannet E, Groen H, Jager PL et ai. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101. (Pubitemid 38240089)
14. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003;44:717-724. (Pubitemid 39655205)
15. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001;42:713-720. (Pubitemid 32453458)
16. Toner GC, Hicks RJ. PET for sarcomas other than gastrointestinal stromal tumors. Oncologist 2008;13(Suppl 2):22-26.
17. Volker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25:5435-5441. (Pubitemid 350232220)
18. Schwab JH, Boland PJ, Antonescu C et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007;110:1815-1822. (Pubitemid 47557307)
19. Gerth HU, Juergens KU, Dirksen U et al. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007;48:1932-1939. (Pubitemid 350237602)
20. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 1999;19:1343-1349. (Pubitemid 29257457)
21. 18F-fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380-386. (Pubitemid 30137126)
22. Beyer T, Townsend DW, Brun T et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379. (Pubitemid 30643379)
23. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433-438.
24. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET Response Criteria in Solid Tumors. J Nucl Med 2009;50:122S-150S.
25. Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-348. (Pubitemid 40129294)
26. Benz MR, Allen-Auerbach MS, Eilber FC et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 2008;49:1579-1584.
27. Benz MR, Evilevitch V, Allen-Auerbach MS et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 2008;49:1038-1046. (Pubitemid 351948010)
28. Evilevitch V, Weber WA, Tap WD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008;14:715-720. (Pubitemid 351231152)
29. Benz MR, Czernin J, Allen-Auerbach MS et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high grade soft tissue sarcomas. Clin Cancer Res 2009;15:2856-2863.
30. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107-112. (Pubitemid 351348089)
31. Kasper B, Schmitt T, Wuchter P et al. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Mar Drugs 2009;7:331-340.
32. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-1154. (Pubitemid 34985359)
33. 18F-fluorodeoxyglucose positron emission tomography imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241:286-294.
34. Brenner W, Friedrich RE, Gawad KA et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006;33:428-432.
35. 18F-FDG uptake as a predictor of patient outcome. J Nucl Med 2008;49:1973-1979.
36. Benz MR, Tchekmedyian N, Eilber FC et al. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol 2009;21:345-351.
37. Okazumi S, Dimitrakopoulou-Strauss A, Schwarzbach MH, Strauss LG. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas. Hell J Nucl Med 2009;12:223-228.